Skip to main content
Premium Trial:

Request an Annual Quote

CytRx's RXi Business Exclusively Licenses Invitrogen's RNAi IP for Rx Apps

NEW YORK (GenomeWeb News) — CytRx subsidiary RXi Pharmaceuticals will exclusively license Invitrogen’s second-generation RNAi technology for “designated target genes in all human therapeutic categories,” the companies said today.
The intellectual property covers Invitrogen’s Stealth technology and other tools related to chemically modified double-stranded RNA.
RXi CEO Tod Woolf said in a statement that the deal is “part of our strategy to enhance our proprietary rxRNA compounds for therapeutic applications.”
CytRx currently owns three clinical-stage compounds that use its small-molecule “molecular chaperone” co-induction technology, including candidates to treat amyotrophic lateral sclerosis, diabetic foot ulcers, and stroke recovery.
Invitrogen’s Stealth RNAi synthetic duplexes are used for RNAi research across both in vitro and in vivo applications, Amy Butler, Invitrogen vice president of gene-expression profiling, said in a statement.
She said the company sees the use of the technology in therapeutics as “a natural next step in Invitrogen’s efforts to be at the cutting edge of in vivo gene regulation.”

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.